Mostrar el registro sencillo del ítem

dc.contributor.authorRomero-Sanz, Silvia
dc.contributor.authorCaldero Escudero, Elena
dc.contributor.authorÁlvarez Illera, María Pilar
dc.contributor.authorSanto Domingo Mayoral, Jaime
dc.contributor.authorFonteriz García, Rosalba Inés 
dc.contributor.authorMontero Zoccola, María Teresa 
dc.contributor.authorÁlvarez Martín, Javier 
dc.date.accessioned2024-02-13T16:03:39Z
dc.date.available2024-02-13T16:03:39Z
dc.date.issued2023
dc.identifier.citationFrontiers in Pharmacology, May 2023, 14, 1182428es
dc.identifier.issn1663-9812es
dc.identifier.urihttps://uvadoc.uva.es/handle/10324/66237
dc.descriptionProducción Científicaes
dc.description.abstractIntroduction: The high prevalence of neurodegenerative diseases in our population and the lack of effective treatments encourage the search for new therapeutic targets for these pathologies. We have recently described that submaximal inhibition of the Sarco-Endoplasmic Reticulum Ca2+ ATPase (SERCA), the main responsible for ER calcium storage, is able to increase lifespan in Caenorhabditis elegans worms by mechanisms involving mitochondrial metabolism and nutrient-sensitive pathways. Methods: We have studied here the effects of submaximal SERCA inhibition in a chemical model of Parkinson’s disease (PD) induced in C. elegans worms by treatment with the mitochondrial complex I inhibitor rotenone. For specific SERCA inhibition,we treated worms with RNAi against sca-1, the sole orthologue of SERCA in C. elegans. Results and Discussion: Our results show that rotenone produces alterations in worms that include decreased lifespan, smaller size, reduced fertility, decreased motility, defecation and pumping rate, increased mitochondrial ROS production, reduced mitochondrial membrane potential and oxygen consumption rate, altered mitochondrial structure, and altered ethanol preference in behavioral studies. Most of these alterations were either fully or partially reversed in worms treated with sca-1 RNAi, suggesting that SERCA inhibition could be a novel pharmacological target in the prevention or treatment of neurodegeneration.es
dc.format.mimetypeapplication/pdfes
dc.language.isoenges
dc.publisherFrontierses
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subject.classificationC. elegans, rotenone, Parkinson’s disease, SERCA, lifespan, endoplasmic reticulum, mitochondria, Ca2+ signalinges
dc.titleSERCA inhibition improves lifespan and healthspan in a chemical model of Parkinson disease in Caenorhabditis eleganses
dc.typeinfo:eu-repo/semantics/articlees
dc.identifier.doi10.3389/fphar.2023.1182428es
dc.relation.publisherversionhttps://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2023.1182428/fulles
dc.identifier.publicationtitleFrontiers in Pharmacologyes
dc.identifier.publicationvolume14es
dc.peerreviewedSIes
dc.description.projectMICINN project BFU2017-83509-Res
dc.description.projectMICINN project PID 2021-122239OB-I00es
dc.identifier.essn1663-9812es
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersiones


Ficheros en el ítem

Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem